Abstract
Importance Understanding the cognitive trajectory of a neurological disease can provide important insight on underlying mechanisms and disease progression. Cognitive impairment is now well established as beginning many years before the diagnosis of Alzheimer’s disease, but pre-diagnostic profiles are unclear for other neurological conditions that may be associated with cognitive impairment.
Objective Compare pre-diagnostic and post-diagnostic cognition and global brain volume in ischaemic stroke, focal epilepsy, Parkinson’s disease, multiple sclerosis, motor neurone disease (amyotrophic lateral sclerosis) and migraine using time-to-diagnosis and time-from-diagnosis data in relation to time of assessment.
Design Analysis the prospective UK Biobank cohort with study baseline assessment performed between 2006-2010 and participants followed until 2021.
Setting Multicenter, population-based study.
Participants Sample of 497,252 participants, aged between 38 and 72 years, at baseline with an imaging sub-sample of 42,468 participants.
Exposure Participants with each neurological condition were compared to a healthy control group.
Main outcomes and measures A continuous measure of executive function and magnetic resonance imaging brain measures of total grey matter and hippocampal volume.
Results Of the 497,252 participants (226,206 [45.5%] men, mean [SD] age, 57.5[8.1] years), 12,755 had ischaemic stroke, 6,758 had a diagnosis of focal epilepsy, 3,315 had Parkinson’s disease, 2,315 had multiple sclerosis, 559 had motor neurone disease and 18,254 had migraine either at study baseline or diagnosed during the follow-up period. Apart from motor neurone disease, all conditions had lower pre-diagnosis executive function compared to controls (assessment performed median 7.4 years before diagnosis). Participants with focal epilepsy and multiple sclerosis showed a gradual worsening in executive function up to 15 years prior to diagnosis, while ischaemic stroke was characterised by a modest decline for a few years followed by a substantial reduction at the time of diagnosis. By contrast, participants with migraine showed improved post-diagnosis cognitive scores. Pre-diagnosis MRI grey matter volume was lower than controls for stroke, Parkinson’s disease and multiple sclerosis (scans performed median 1.7 years before diagnosis), while other conditions had lower volumes post-diagnosis.
Conclusion These cognitive trajectory models reveal disease-specific temporal patterns, including a long cognitive prodrome associated with focal epilepsy and multiple sclerosis. The findings may help to prioritise risk management of individual diseases and inform clinical decision-making.
Question What is the pre-diagnosis cognitive profile across neurological conditions of ischaemic stroke, focal epilepsy, Parkinson’s disease, multiple sclerosis, motor neurone disease and migraine?
Findings This cohort study of 495 149 participants, aged between 38 and 72 years, identified gradual worsening of cognition up to 15 years prior to clinical diagnosis in participants with focal epilepsy and multiple sclerosis while stroke was associated with a modest decline for a few years followed by a substantial reduction at the time of diagnosis. Migraine was associated with post-diagnosis improvement in cognitive scores.
Meaning Cognitive trajectory models identify disease-specific temporal patterns that may help to prioritise risk management of individual diseases and inform clinical decision-making.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was funded by the Wellcome Trust (Wellcome Trust PhD clinical fellowship to XYT and Wellcome Trust Principal Research Fellowship to MH [206330/Z/17/Z]) and MRC (Clinician Scientist Fellowship to S.M. [MR/P00878/X]) and by the Oxford NIHR Biomedical Research Centre.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study examines the UK Biobank, a population-based cohort of over 500 000 participants aged 38-72 years who underwent physiological measurements, cognitive testing and provided biological samples at one of 22 centres across the UK between 2006 and 2010.20 A subset re-attended for brain imaging between 2014 and 2020.21 All participants provided written informed consent. UK Biobank received approved from the North-West Multi-centre Research Ethics Committee (REC number 21/NW/0157).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The data analysed during the current study are available from the UK Biobank https://www.ukbiobank.ac.uk/researchers/. The variables used are detailed in Supplementary Table 1. This research was conducted using the UK Biobank resource under application 9462.
